Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study Treatment was center of $1 billion buyout

https://www.statnews.com/2026/05/25/eli-lilly-verv-102-gene-editing-cholesterol-phase-1-trial-data/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9jih8AOmLYTNhfcako_Oakyta8q3YBhmCNx-22C4RPQCQh1ppFLeOtxiuw3u4axGqr_mvd59Ax_6XhGYoAm2Gr2_7guA&_hsmi=420539245&utm_content=420539245&utm_source=hs_email By Jason MastMay 25, 2026 General Assignment Reporter Lilly's one-time cholesterol edit shows promise Eli Lilly’s experimental gene-editing therapy lowered LDL cholesterol by 62% in an early-stage trial. The treatment, acquired through Lilly’s $1 billion buyout of Verve Therapeutics, works by permanently disabling PCSK9 in the liver through a single-letter DNA edit. It suggests that a one-time DNA edit could someday replace lifelong cholesterol medication. “The results appear durable (likely permanent),” Steven Nissen, a cardiologist at the Cleveland Clinic, said in an email. Importantly, researchers reported no treatment-related serious adverse events, STAT’s Jason Mast writes — a notable outcome after Verve abandoned an earlier candidate over safety concerns. The data, published in the NEJM, showed LDL reductions lasting up to 575 days in lower-dose cohorts. Still, major questions remain about whether patients will embrace irreversible gene editing when existing PCSK9 drugs already work well with periodic dosing